Vanda Pharmaceuticals (VNDA) Accounts Payables (2010 - 2026)

Vanda Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $60.6 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 33.88% year-over-year to $60.6 million; the TTM figure through Mar 2026 stood at $60.6 million (up 33.88% YoY), while the FY2025 annual figure was $68.3 million, up 74.74% from the prior year.
• Accounts Payables came in at $60.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $68.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $68.3 million in Q4 2025 to a low of $31.9 million in Q2 2023.
• A 5-year average of $45.3 million and a median of $45.3 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 96.87% in 2022 and slumped 36.44% in 2023, its largest moves.
• Vanda Pharmaceuticals' Accounts Payables stood at $45.6 million in 2022, then slipped by 15.57% to $38.5 million in 2023, then climbed by 1.63% to $39.1 million in 2024, then surged by 74.74% to $68.3 million in 2025, then fell by 11.24% to $60.6 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $60.6 million, $68.3 million, and $47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison